“The Geneious team has done an excellent job accommodating our specific data, resulting in a streamlined, high-throughput workflow that produces accurate data and operates efficiently without the need to integrate multiple bioinformatics platforms. We look forward to continuously improving the platform and its integration into our workflow to combine sequence analytics with metadata and assay data to accelerate candidate selection.”
Dr. Colby Souders, Chief Technology Officer at Abveris
Abveris is a premium Boston-area contract research organization specializing in antibody discovery. Abveris partners with large and small biopharmaceutical companies to discover novel therapeutic products and critical reagent antibodies using diverse platforms. Additional information about Abveris is available at www.abveris.com.
Bicycle Therapeutics is developing a new class of medicines to treat oncology and other important diseases based on its proprietary bicyclic peptide (Bicycle®) product platform. Bicycle Therapeutics is headquartered in Cambridge, U.K., with a U.S. subsidiary in Cambridge, Massachusetts. For more information, visit www.bicycletherapeutics.com
“We are evolving from a cottage industry to an industrialized process, part of our challenge is ensuring our data maintains integrity and consistency with that evolution. We need software that can work with our unique Bicycle® platform and take our data quality to the next level. Working with Geneious Biologics to apply this application to the analysis of our unique data sets has been enabling for Bicycle Therapeutics and I can see how this could drastically improve speed and accuracy in other areas of drug development.”
Michael Skynner, Ph.D., Vice President of Operations at Bicycle Therapeutics
“We are processing increasingly larger sets of antibody sequences. Geneious Biologics allows us to drill into huge antibody sequence sets and quickly identify where errors lie and inspect bad clones. This will ensure we return the most effective, stable therapeutic antibody candidates to our clients, faster.”
Daniela Teixeira, COO at FairJourney Biologics
“IONTAS has used the Geneious Biologics platform in the development of bespoke fusion molecules and a novel antibody-like scaffold. Geneious Biologics’ flexibility lets us run detailed analysis on these unique, proprietary therapeutic candidates. The platform has been widely adopted within IONTAS and provides the tools to automate many previously manual and time-consuming aspects of sequence analysis. It has significantly improved the way we do sequence analysis and has facilitated the adoption of Next Generation Sequencing (NGS) methods.”
Aneesh Karatt-Vellatt, Group Leader at IONTAS (KnotBodyTM drug discovery)
Often you have to shoehorn a software solution into your process, the adaptability of Geneious Biologics was something we liked a lot. Once we knew what we could do with Geneious Biologics there was no other viable option.
Companies of our size and nature appreciate working with companies of the same mindset. The advantage with Geneious Biologics is – it is scientists talking to scientists.
New technologies like Geneious Biologics will play an important role in allowing researchers to better leverage existing molecular data sets.
IONTAS is focused on the development of novel antibody therapeutics. We chose Geneious Biologics as our core software platform for analysis of antibody sequences because of the company’s willingness and ability to meet our specific needs.
IONTAS had a requirement for processing large quantities of data from both our service based antibody discovery projects and our internal developments. The collaboration has been close and resulted in Geneious Biologics delivering a software solution that has significantly improved the efficiency and scope of our sequence analysis workflows during therapeutic antibody discovery.